Basic Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 14, 2024; 30(14): 2038-2058
Published online Apr 14, 2024. doi: 10.3748/wjg.v30.i14.2038
Comparative transcriptomic analysis reveals the molecular changes of acute pancreatitis in experimental models
Pan Zheng, Xue-Yang Li, Xiao-Yu Yang, Huan Wang, Ling Ding, Cong He, Jian-Hua Wan, Hua-Jing Ke, Nong-Hua Lu, Nian-Shuang Li, Yin Zhu
Pan Zheng, Xue-Yang Li, Xiao-Yu Yang, Huan Wang, Ling Ding, Cong He, Jian-Hua Wan, Hua-Jing Ke, Nong-Hua Lu, Nian-Shuang Li, Yin Zhu, Department of Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, Jiangxi Province, China
Co-corresponding authors: Yin Zhu and Nian-Shuang Li.
Author contributions: Zhu Y and Li NS designed and coordinated the study; Zheng P and Li XY completed the experimental testing and wrote the article; Wan JH and Yang XY were in charge of animal modeling; He C and Ke HJ were responsible for data download and analysis in GEO database; Ding L and Wang H bred transgenic mouse; Zhu Y, Lu NH and Li NS revised and verified the article; all authors were involved in the critical review of the results and have contributed to, read, and approved the final manuscript. The reason for choosing Zhu Y and Li NH as co-corresponding authors is that Zhu Y and Li NH have made equal efforts in the whole research process, played a common important role in the design and guidance of the paper, and ensured the quality and reliability of the paper. Pan Z and Li XY contributed equally to this article.
Supported by National Natural Science Foundation of China, No. 82260133 and No. 82370661; the Academic and Technical Leader of major disciplines in Jiangxi Province, No. 20225BCJ23021; the Jiangxi Medicine Academy of Nutrition and Health Management, No. 2022-PYXM-01; the Natural Science Foundation of Jiangxi Province, No. 20224ACB216004; and the Technological Innovation Team Cultivation Project of the First Affiliated Hospital of Nanchang University, No. YFYKCTDPY202202.
Institutional animal care and use committee statement: The First Affiliated Hospital of Nanchang University approved experimental animal welfare ethics Approved by the Experimental Animal Welfare Ethics Committee of the First Affiliated Hospital of Nanchang University, Zhu Yin, Gastroenterology Department of our Hospital, "Research on the mechanism of Bifidobacterium pseudolongum Protecting intestinal mucosal Barrier in acute pancreatitis by activating NOD2-autophagy signal axis" (Approval number: CDYFYIACUC-202306QR022), does not violate the ethical principles of experimental animal welfare, and agrees to carry out the research under the approved protocol. Experimental animal Welfare Ethics Committee of the First Affiliated Hospital of Nanchang University
Conflict-of-interest statement: The authors declare that they have no competing interests.
Data sharing statement: The first author obtained two files, GSE109227 and GSE194331, from the public database GEO for validation purposes.
ARRIVE guidelines statement: The authors have read the ARRIVE Guidelines, and the manuscript was prepared and revised according to the ARRIVE Guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yin Zhu, MD, PhD, Chief Doctor, Department of Gastroenterology, Digestive Disease Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 17 Yongwaizheng Street, Donghu District, Nanchang 330006, Jiangxi Province, China. ndyfy01977@ncu.edu.cn
Received: December 8, 2023
Peer-review started: December 8, 2023
First decision: January 4, 2024
Revised: January 19, 2024
Accepted: March 1, 2024
Article in press: March 1, 2024
Published online: April 14, 2024
Processing time: 126 Days and 14.5 Hours
Abstract
BACKGROUND

Acute pancreatitis (AP) encompasses a spectrum of pancreatic inflammatory conditions, ranging from mild inflammation to severe pancreatic necrosis and multisystem organ failure. Given the challenges associated with obtaining human pancreatic samples, research on AP predominantly relies on animal models. In this study, we aimed to elucidate the fundamental molecular mechanisms underlying AP using various AP models.

AIM

To investigate the shared molecular changes underlying the development of AP across varying severity levels.

METHODS

AP was induced in animal models through treatment with caerulein alone or in combination with lipopolysaccharide (LPS). Additionally, using Ptf1α to drive the specific expression of the hM3 promoter in pancreatic acinar cells transgenic C57BL/6J- hM3/Ptf1α(cre) mice were administered Clozapine N-oxide to induce AP. Subsequently, we conducted RNA sequencing of pancreatic tissues and validated the expression of significantly different genes using the Gene Expression Omnibus (GEO) database.

RESULTS

Caerulein-induced AP showed severe inflammation and edema, which were exacerbated when combined with LPS and accompanied by partial pancreatic tissue necrosis. Compared with the control group, RNA sequencing analysis revealed 880 significantly differentially expressed genes in the caerulein model and 885 in the caerulein combined with the LPS model. Kyoto Encyclopedia of Genes and Genomes enrichment analysis and Gene Set Enrichment Analysis indicated substantial enrichment of the TLR and NOD-like receptor signaling pathway, TLR signaling pathway, and NF-κB signaling pathway, alongside elevated levels of apoptosis-related pathways, such as apoptosis, P53 pathway, and phagosome pathway. The significantly elevated genes in the TLR and NOD-like receptor signaling pathways, as well as in the apoptosis pathway, were validated through quantitative real-time PCR experiments in animal models. Validation from the GEO database revealed that only MYD88 concurred in both mouse pancreatic tissue and human AP peripheral blood, while TLR1, TLR7, RIPK3, and OAS2 genes exhibited marked elevation in human AP. The genes TUBA1A and GADD45A played significant roles in apoptosis within human AP. The transgenic mouse model hM3/Ptf1α(cre) successfully validated significant differential genes in the TLR and NOD-like receptor signaling pathways as well as the apoptosis pathway, indicating that these pathways represent shared pathological processes in AP across different models.

CONCLUSION

The TLR and NOD receptor signaling pathways play crucial roles in the inflammatory progression of AP, notably the MYD88 gene. Apoptosis holds a central position in the necrotic processes of AP, with TUBA1A and GADD45A genes exhibiting prominence in human AP.

Keywords: Acute pancreatitis; RNA-sequencing; Experimental acute pancreatitis models; Inflammatory; Apoptosis; TLR and NOD-like signaling pathways

Core Tip: AP is a critical emergency condition with no effective targeted therapeutic interventions currently available. Therefore, RNA sequencing (RNA-seq) was employed to investigate the molecular alterations in acute pancreatitis (AP), aiming to identify novel therapeutic strategies. The RNA-seq analysis showed a significant upregulation of TLR and NOD-like signaling pathways in AP, with crucial involvement of genes such as TLR7, IRF7, and MYD88. Notably, the TUBA1A and GADD45A genes were identified as key players in the apoptosis signaling pathway. Substantial evidence was provided through comprehensive validation using Gene Expression Omnibus Series datasets from human peripheral blood and mouse pancreatic tissues, as well as transgenic mouse models to examine inflammation and apoptosis-related molecules. This study offers fresh insights for future therapeutic approaches in managing AP and establishes new directions for subsequent fundamental investigations.